Cue Biopharma (CUE) Income from Continuing Operations (2018 - 2025)
Historic Income from Continuing Operations for Cue Biopharma (CUE) over the last 8 years, with Q3 2025 value amounting to -$7.4 million.
- Cue Biopharma's Income from Continuing Operations rose 1297.21% to -$7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$37.3 million, marking a year-over-year increase of 1421.73%. This contributed to the annual value of -$39.9 million for FY2024, which is 1941.88% up from last year.
- According to the latest figures from Q3 2025, Cue Biopharma's Income from Continuing Operations is -$7.4 million, which was up 1297.21% from -$8.4 million recorded in Q2 2025.
- Over the past 5 years, Cue Biopharma's Income from Continuing Operations peaked at -$7.4 million during Q3 2025, and registered a low of -$14.3 million during Q1 2022.
- Moreover, its 5-year median value for Income from Continuing Operations was -$12.1 million (2024), whereas its average is -$11.2 million.
- Per our database at Business Quant, Cue Biopharma's Income from Continuing Operations tumbled by 8042.44% in 2022 and then soared by 2772.49% in 2024.
- Quarter analysis of 5 years shows Cue Biopharma's Income from Continuing Operations stood at -$7.9 million in 2021, then plummeted by 80.42% to -$14.2 million in 2022, then rose by 9.18% to -$12.9 million in 2023, then rose by 27.72% to -$9.3 million in 2024, then grew by 21.09% to -$7.4 million in 2025.
- Its Income from Continuing Operations stands at -$7.4 million for Q3 2025, versus -$8.4 million for Q2 2025 and -$12.1 million for Q1 2025.